Galectin-1 (Gal1), an evolutionarily conserved glycan-binding protein, contributes to the creation of an immunosuppressed microenvironment at sites of tumor growth. In spite of considerable progress in elucidating its role in tumor-immune escape, the mechanisms underlying the inhibitory functions of Gal1 remain obscure. Here, we investigated the contribution of tumor Gal1 to tumor growth, metastasis, and immunosuppression in breast cancer. We found that the frequency of Gal1(+) cells in human breast cancer biopsies correlated positively with tumor grade, while specimens from patients with benign hyperplasia showed negative or limited Gal1 staining. To examine the pathophysiologic relevance of Gal1 in breast cancer, we used the metastatic mo...
The immune system has developed along with the evolution of increasingly complex cellular organisms...
Figure S1. RNA sequencing analysis of GLO1-depleted MDA-MB-231 cells. (A) MG extracellular concentra...
Although cancers develop and progress in immunocompetent hosts, immunological therapies for cancer h...
Flavonoids were proposed as chemopreventive and chemotherapeutic agents per se or in combination wit...
Breast cancer is the disease with the highest impact on global health, beingmetastasis the main caus...
Colorectal cancer (CRC) represents the third most common malignancy and the second leading cause of ...
The identification of effective new therapies for prostate cancer (PCa) requires a better understand...
Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal tumor types, with extremely lo...
Galectins, a family of glycan-binding proteins, can control tumor progression by promoting transform...
Tumors escape from immune surveillance by producing immunosuppressive cytokines and proapototic fact...
BACKGROUND: No curative therapy is currently available for metastatic prostate cancer (PCa). The div...
Tumor cells corrupt surrounding normal cells instructing them to support proliferative, pro-angiogen...
Breast cancer is the second leading cause of cancer related death in women worldwide1. Although majo...
Despite the existence of tumor-specific immune cells, most tumors have devised strategies to avoid i...
Despite significant advances in biology and medicine, the incidence and mortality due to breast canc...
The immune system has developed along with the evolution of increasingly complex cellular organisms...
Figure S1. RNA sequencing analysis of GLO1-depleted MDA-MB-231 cells. (A) MG extracellular concentra...
Although cancers develop and progress in immunocompetent hosts, immunological therapies for cancer h...
Flavonoids were proposed as chemopreventive and chemotherapeutic agents per se or in combination wit...
Breast cancer is the disease with the highest impact on global health, beingmetastasis the main caus...
Colorectal cancer (CRC) represents the third most common malignancy and the second leading cause of ...
The identification of effective new therapies for prostate cancer (PCa) requires a better understand...
Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal tumor types, with extremely lo...
Galectins, a family of glycan-binding proteins, can control tumor progression by promoting transform...
Tumors escape from immune surveillance by producing immunosuppressive cytokines and proapototic fact...
BACKGROUND: No curative therapy is currently available for metastatic prostate cancer (PCa). The div...
Tumor cells corrupt surrounding normal cells instructing them to support proliferative, pro-angiogen...
Breast cancer is the second leading cause of cancer related death in women worldwide1. Although majo...
Despite the existence of tumor-specific immune cells, most tumors have devised strategies to avoid i...
Despite significant advances in biology and medicine, the incidence and mortality due to breast canc...
The immune system has developed along with the evolution of increasingly complex cellular organisms...
Figure S1. RNA sequencing analysis of GLO1-depleted MDA-MB-231 cells. (A) MG extracellular concentra...
Although cancers develop and progress in immunocompetent hosts, immunological therapies for cancer h...